USPTO serial 86613157
NDC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- PARK, JENNY K
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with NDC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Elizabeth A. Walker
ELIZABETH A. WALKER Choate Hall2 International Pl Ste 3200Boston, MA 02110-4120UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for diagnosis and targeted treatment of cancer and tumor diseases; pharmaceutical preparations and substances for diagnosis and treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; therapeutic agents for diagnosis and targeted treatment of cancer and tumor diseases; therapeutic agents for diagnosis and treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; therapeutic pharmaceuticals and substances for the diagnosis and treatment of viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; pharmaceutical preparations and substances for diagnosis and treatment of diseases and disorders; therapeutic agents for diagnosis and treatment of diseases and disorders | ACTIVE | — |
| 042 | Research and development in the fields of pharmaceuticals, biotechnology, therapeutics, and drug formulation and delivery; research and development in the field of targeted therapies for cancer and tumor diseases; research and development in the field of targeted therapies for viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, inflammatory, dermatological, psychiatric and immune system related diseases and disorders; consulting services in the field of scientific research; consulting services in the field of research and development for pharmaceuticals, biotechnology, therapeutics, and drug formulation and delivery; consulting services in the field of clinical trials; testing, inspection, research, or development of pharmaceutical and therapeutic preparations; pharmaceutical and therapeutic drug development services; pharmaceutical and therapeutic product evaluation; conducting early evaluations in the field of new pharmaceuticals and therapeutics; conducting quality control testing, feasibility testing, toxicology testing and pharmacology testing for pharmaceuticals and therapeutics; laboratory research services relating to pharmaceuticals and therapeutics; medical and scientific research, namely, conducting clinical trials for others; product safety testing for pharmaceuticals and therapeutics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Memorial Sloan Kettering Cancer Center
- Other trademarks owned by Memorial Sloan Kettering Cancer Center
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named NDC
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 1, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 1, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 30, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 29, 2018 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Nov 29, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 19, 2018 | EXT5 | SOU EXTENSION 5 FILED | — |
| Nov 19, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 15, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 11, 2018 | EX4G | SOU EXTENSION 4 GRANTED | — |
| May 11, 2018 | EXT4 | SOU EXTENSION 4 FILED | — |
| May 11, 2018 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 27, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 25, 2017 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Oct 25, 2017 | EXT3 | SOU EXTENSION 3 FILED | — |
| Oct 25, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 12, 2017 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 10, 2017 | EX2G | SOU EXTENSION 2 GRANTED | — |
| May 10, 2017 | EXT2 | SOU EXTENSION 2 FILED | — |
| May 10, 2017 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 8, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 4, 2016 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 4, 2016 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 4, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 31, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 5, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 5, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 16, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 2, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Feb 25, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 25, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 18, 2016 | ALIE | ASSIGNED TO LIE | — |
| Feb 11, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 12, 2015 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 12, 2015 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 12, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 6, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| May 9, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 1, 2015 | NWAP | NEW APPLICATION ENTERED | — |